×
About 22,712 results

ALLMedicine™ Hypercholesterolemia Center

Research & Reviews  8,729 results

Evinacumab (Evkeeza) for homozygous familial hypercholesterolemia.
https://www.ncbi.nlm.nih.gov/pubmed/33976097
The Medical Letter on Drugs and Therapeutics;

May 12th, 2021 - Evinacumab (Evkeeza) for homozygous familial hypercholesterolemia.|2021||

Pleiotropy of systemic lupus erythematosus risk alleles and cardiometabolic disorders: ...
https://doi.org/10.1177/09612033211014952
Lupus Kawai VK, Shi M et. al.

May 12th, 2021 - To test the hypothesis that genetic predisposition to systemic lupus erythematosus (SLE) increases the risk of cardiometabolic disorders. Using 41 single nucleotide polymorphisms (SNPs) associated with SLE, we calculated a weighted genetic risk sc...

Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase 1/2 Trial to S...
https://doi.org/10.1002/cpt.2228
Clinical Pharmacology and Therapeutics; Chen J, Ruiz-Garcia A et. al.

May 11th, 2021 - Lorlatinib is a small molecule inhibitor of anaplastic lymphoma kinase (ALK) and c-ROS oncogene 1 (ROS1) tyrosine kinases and is approved for the treatment of patients with ALK-positive advanced non-small cell lung cancer (NSCLC). In the Phase 1/2...

Hypertension and Hypercholesterolemia Modify Dementia Risk in Relation to APOEɛ4 Status.
https://doi.org/10.3233/JAD-201609
Journal of Alzheimer's Disease : JAD; Pillai JA, Lei K et. al.

May 10th, 2021 - There is significant interest in understanding the role of modifiable vascular risk factors contributing to dementia risk across age groups. Risk of dementia onset was assessed in relation to vascular risk factors of hypertension and hypercholeste...

see more →

Guidelines  27 results

Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
https://esperion.gcs-web.com/node/11206/pdf

Feb 24th, 2020 - Esperion announced today that the U.S. Food and Drug Administration (FDA) approved NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. NEXLETOL is indicated as an adjunct to diet and maxima...

Statin Use and the Site-Specific Risk of Colorectal Cancer in Individuals with Hypercholesterolemia from the National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS)
https://www.sciencedirect.com/science/article/pii/S0939475319301164?via%3Dihub
Nutrition, Metabolism and Cardiovascular Diseases; Lee,J.,et al

Apr 12th, 2019 - Background and Aims We investigated the association between statin use and site-specific risk of colorectal cancer in individuals with hypercholesterolemia. Methods and Results This study is based on the National Health Insurance Service-National...

Lipid levels and the risk of hemorrhagic stroke among women
https://n.neurology.org/content/early/2019/04/10/WNL.0000000000007454
Rist,P.,et al

Apr 9th, 2019 - Objective To examine the association between lipid levels and hemorrhagic stroke risk among women. Methods We performed a prospective cohort study among 27,937 women enrolled in the Women's Health Study with measured total cholesterol, low-densit...

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Up...
https://doi.org/10.1016/j.cjca.2018.09.005
The Canadian Journal of Cardiology; Brunham LR, Ruel I et. al.

Dec 11th, 2018 - Familial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are...

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of ...
http://www.onlinejacc.org/content/early/2018/11/02/j.jacc.2018.11.003
Grundy, S.,et al

Nov 9th, 2018 - The recommendations listed in the present guideline are, whenever possible, evidence based. An initial extensive evidence review, which included literature derived from research involving human subjects, published in English, and indexed in MEDLIN.

see more →

Drugs  1,881 results see all →

Clinicaltrials.gov  11,269 results

Evinacumab (Evkeeza) for homozygous familial hypercholesterolemia.
https://www.ncbi.nlm.nih.gov/pubmed/33976097
The Medical Letter on Drugs and Therapeutics;

May 12th, 2021 - Evinacumab (Evkeeza) for homozygous familial hypercholesterolemia.|2021||

Pleiotropy of systemic lupus erythematosus risk alleles and cardiometabolic disorders: ...
https://doi.org/10.1177/09612033211014952
Lupus Kawai VK, Shi M et. al.

May 12th, 2021 - To test the hypothesis that genetic predisposition to systemic lupus erythematosus (SLE) increases the risk of cardiometabolic disorders. Using 41 single nucleotide polymorphisms (SNPs) associated with SLE, we calculated a weighted genetic risk sc...

Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase 1/2 Trial to S...
https://doi.org/10.1002/cpt.2228
Clinical Pharmacology and Therapeutics; Chen J, Ruiz-Garcia A et. al.

May 11th, 2021 - Lorlatinib is a small molecule inhibitor of anaplastic lymphoma kinase (ALK) and c-ROS oncogene 1 (ROS1) tyrosine kinases and is approved for the treatment of patients with ALK-positive advanced non-small cell lung cancer (NSCLC). In the Phase 1/2...

Hypertension and Hypercholesterolemia Modify Dementia Risk in Relation to APOEɛ4 Status.
https://doi.org/10.3233/JAD-201609
Journal of Alzheimer's Disease : JAD; Pillai JA, Lei K et. al.

May 10th, 2021 - There is significant interest in understanding the role of modifiable vascular risk factors contributing to dementia risk across age groups. Risk of dementia onset was assessed in relation to vascular risk factors of hypertension and hypercholeste...

see more →

News  801 results

An Expert's Guide to Managing Familial Hypercholesterolemia
https://www.medscape.com/viewarticle/948546

Apr 20th, 2021 - This transcript has been edited for clarity. Hi. I'm Seth Baum, a preventive cardiologist and clinical lipidologist in Boca Raton, Florida. I'm also the past president of the American Society for Preventive Cardiology and on the faculty at the Flo...

FDA Okays New Indication for Alirocumab in Homozygous FH
https://www.medscape.com/viewarticle/948580

Mar 31st, 2021 - The US Food and Drug Administration has approved alirocumab (Praluent, Regeneron Pharmaceuticals) injection as add-on therapy for adults with homozygous familial hypercholesterolemia, the agency announced. The proprotein convertase subtilisin/kexi...

Achilles Tendon Softness a New Tool to Diagnose FH
https://www.medscape.com/viewarticle/948460

Mar 30th, 2021 - Achilles tendon softness should be considered a new indicator of familial hypercholesterolemia, in addition to Achilles tendon thickness, researchers suggest. In a cross-sectional study that measured Achilles tendon thickness and elasticity (i. e

FDA Approves Orphan Drug Evinacumab-dgnb for Homozygous FH
https://www.medscape.com/viewarticle/945719

Feb 10th, 2021 - The US Food and Drug Administration has approved the fully human monoclonal antibody evinacumab-dgnb (Evkeeza, Regeneron Pharmaceuticals) for use on top of other cholesterol-modifying meds in patients aged 12 and older with homozygous familial hyp...

Evinacumab, Novel Lipid-Lowerer, Extends Promise in Phase 2 Results
https://www.medscape.com/viewarticle/941043

Nov 15th, 2020 - Treatment with evinacumab, an investigational lipid-lowering drug with a novel mechanism of action, safely led to roughly a halving of LDL cholesterol levels in patients with treatment-refractory hypercholesterolemia in a multicenter, phase 2 stud...

see more →

Patient Education  5 results see all →